18 FDG-SPECT Imaging of Brain Tumours

Abstract

Italian

The purpose of this prospective study was to examine, if it is possible in principal to obtain suitable information to grade brain tumours and detect recurrences in follow up with ¹⁸Fluoro-Deoxyglucose (¹⁸FDG) and Single Photon Emission Computed Tomography (SPECT) using ultra high energy collimators. Fifty two brain SPECT investigations were carried out in 41 patients. Forty patients had primary brain tumours and one an anaplastic meningioma. SPECT acquisition was started 30 min after application of 400 MBq ¹⁸FDG using special high energy 511 KeV collimators.

After attenuation correction (coef.= 0.07 cm^−1/) brain tumour FDG uptake was quantified as ratio to contralateral brain cortex (RUV: relative uptake value). SPECT data were compared with histopathological findings and CT/MR images. In grade 4 gliomas (glioblastomas), ¹⁸FDG uptake depended on the ratio viable tumour tissue, taking up contrast media in CT/MRI, to cystic tumour areas. Two cases showed increased uptake (RUV = 1.33 and 1.05) compared to the contralateral cortex and four with central necrosis a decreased uptake (RUV = 0.79 ± 0.14). Grade 2 gliomas (five cases) showed a decreased ¹⁸FDG uptake (RUV = 0.68 ± 0.02) compared with contralateral brain cortex.

In grade 3 astrocytomas (two cases), ¹⁸FDG uptake was significantly lower than cortex uptake, but slightly increased when compared with white matter uptake (RUV = 0.79 and 0.82). In follow-up, eight patients with a grade 4 glioma recurrence and one patient with a medulloblastoma recurrence showed an increased ¹⁸FDG uptake (RUV = 1.2 ±0.09 and 1.2). In one grade 4 glioma recurrence, SPECT results were false negative showing decreased FDG-uptake due to the presence of necrotic areas induced by radiotherapy. Grade 2 glioma recurrences (eight cases) showed low ¹⁸FDG uptake values (RUV = 0.73 ± 0.11). Radionecrosis also showed a decreased ¹⁸FDG uptake (RUV = 0.64 ± 0.09) compared with unaffected cortex.

These results demonstrate that grading and follow-up tests of brain tumours are possible with ¹⁸FDG-SPECT, although SPECT with high energy collimators provides a relatively poor spatial resolution which requires further technical improvements.

Keywords

SPECT 18-FDG brain neoplasms emission CT (ECT)diagnosis radionuclide imaging

Get full access to this article

View all access options for this article.

References

Larson

Weiden

: Positron imaging feasibility studies: II. Characteristics of 2-deoxyglucose uptake in rodent and canine neoplasms: Concise communication. J Nucl Med 22: 875–879, 1981.

Bessell

Foster

Westwood

: The use of deoxyflu-oro-D-glucopyranoses and related compounds in a study of yeast hexokinase specificity. Biochem J 128: 199–204, 1972.

Reivich

Kuhl

: The (¹⁸F)fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44: 127–137, 1979.

Gallagher

Fowler

: Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of (¹⁸F)2-deoxyglucose. J Nucl Med 19: 1154–1161, 1978.

Minn

Joensuu

: Fluorodeoxyglucose Imaging: A method to assess the proliferative activity of human cancer in vivo. Cancer 61: 1776–1781, 1988.

Di Chiro

Paz

: Glucose utilization of cerebral gliomas measured by (¹⁸F)fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323–1329, 1982.

Di Chiro

: Positron emission tomography using [¹⁸F]fluorodeoxyglucose in brain tumors: A powerful diagnostic and prognostic tool. Invest Radiol 22: 360–371, 1986.

Coleman

Hoffman

: Clinical application of PET for the evaluation of brain tumors. J Nucl Med 32: 616–648, 1991.

Leichner

Morgan

: SPECT imaging of fluorine-18. J Nucl Med 36: 1472–1475, 1995.

10.

Martin

Delbeke

: FDG-SPECT: Correlation with FDG-PET. J Nucl Med 36: 988–995, 1995.

11.

Schaefer

Oberhausen

: Testmessungen an der Multi-spect-2-Gammakamera zum Nachweis von 511-keV-Gam-mastrahlung. Nuklearmedizin 34: 40–46, 1995.

12.

Drane

Abbott

: Technology for FDG SPECT with a relatively inexpensive gamma camera. Work in progress. Radiology 191: 461–465, 1994.

13.

Höflin

Ledermann

: Routine ¹⁸F-2-deoxy-2-fluoro-D-glucose (¹⁸F-FDG) myocardial tomography using a normal large field of view gamma-camera. Angiology 40: 1058–1064, 1989.

14.

Bax

Visser

: Feasibility of assessing regional myocardial uptake of ¹⁸F-fluorodeoxyglucose using single photon emission computed tomography. Eur Heart J 14: 1675–1682, 1993.

15.

Bax

Visser

: Relation between myocardial uptake of thallium-201 chloride and fluorine-18 fluorodeoxyglucose imaged with single-photon emission tomography in normal individuals. Eur J Nucl Med 22:56–60, 1995.

16.

Bax

Visser

: Myocardial F-18 fluorodeoxyglucose imaging by SPECT. Clin Nucl Med 20: 486–490, 1995.

17.

Stoll

Hellwig

: Myocardial metabolic imaging by means of fluorine-18 deoxyglucose/technetium-99m ses-tamibi dual-isotope single-photon emission tomography. Eur J Nucl Med 21: 1085–1093, 1994.

18.

Burt

Perkins

: Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 36: 176–179, 1995.

19.

Macfarlane

Cotton

: Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): Initial evaluation in oncology and comparison with FDG PET. Radiology 194: 425–429, 1995.

20.

Kleihues

Burger

Scheithauer

: Histological typing of tumours of the central nervous system. WHO International Classification of Tumours. Springer, Berlin Heidelberg New York 1993.

21.

Daumas-Duport

Scheithauer

: Grading of astrocytomas. A simple and reproducible method. Cancer 62: 2152–2165, 1988.

22.

Schaefer

Reiche

: Single Photon Emission Computed Tomography of Brain Tumours Using ¹⁸Fluorodeoxyglucose: Methodical Aspects and First Results. (abstr.) Eur J Nucl Med 22: 809, 1995.

23.

Schwaiger

Hicks

: The clinical role of metabolic imaging of the heart by positron emission tomography. J Nucl Med 32: 565–578, 1991.

24.

Gould

: PET perfusion imaging and nuclear cardiology. J Nucl Med 32: 579–606, 1991.

25.

Frackowiak

RSJ

Wise

RSJ

: Positron Tomography in ischemic cerebrovascular disease. Neurologic clinics 1: 183–200, 1983.

26.

Powers

Raichle

: Positron emission tomograpy and its application to the study of cerebrovascular disease in man. Stroke 16: 361–376, 1985.

27.

Engel

Henry

: Presurgical evaluation for partial epilepsy: Relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG. Neurology 40: 1670–1677, 1990.

28.

Engel

Henry

Risinger

: The role of positron emission tomography in presurgical evaluation of temporal lobe epilepsy. In: Lüders

, (ed): Epilepsy surgery. Ravens Press, New York 1991: 231–141.

29.

Fukuyama

Ogawa

: Altered cerebral energy metabolism in Alzheimer's disease: A PET study. J Nucl Med 35: 1–6, 1994.

30.

Strauss

Conti

: The application of PET in clinical oncology. J Nucl Med 32: 623–648, 1991.

31.

Conti

Keppler

Halls

: Positron Emission Tomography: A financial and operational analysis. Am J Roentgenol 162: 1279–1286, 1994.

32.

Newiger

Jordan

: Optimization of collimators for imaging positron emitters by a gamma camera. Eur J Nucl Med 11: 230–234, 1985.

33.

Van Lingen

Huijgens

: Performance characteristics of a 511-KeV collimator for imaging positron emitters with a standard gamma-camera. Eur J Nucl Med 19: 315–321, 1992.

34.

Franke

Henning

: Knochendiagnostik mit ¹⁸F-Natrium-Hexafluoroalumiante. Dtsch Gesundheitsw 27: 1814–1819, 1972.

35.

Shirazi

Rayudu

Fordham

: ¹⁸F bone scanning: Review of indications and results of 1,500 scans. Radiology 112: 361–368, 1974.

36.

Mukherji

Drane

: Comparison of Thallium-201 and F-18 FDG SPECT uptake in squamous cell carcinoma of the head and neck. Am J Neuroradiol 15: 1837–1842, 1994.

37.

Hoekstra

van Lingen

: Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med 20: 1214–1217, 1993.

38.

Trampert

Holle

Berberich

: ¹⁸FDG beim primären Staging von Lungentumoren. Nuklearmedizin 34: 79–86, 1995.

39.

Martin

Delbeke

: Detection of malignancies with SPECT versus PET, with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose. Radiology 198: 225–231, 1996.

40.

Wienhard

Wagner

Heiss

: PET - Grundlagen und Anwendungen der Positronen-Emissions-Tomographie. Springer, Berlin Heidelberg 1989, 120–153.

41.

Biersack

Coenen

: Imaging of brain tumors with L-3-[123I]Iodo-α-Methyl Tyrosine and SPECT. J Nucl Med 30: 110–112, 1989.

42.

Langen

Roosen

: Brain and brain tumor uptake of L-3-[123I]Iodo-α-Methyl Tyrosine: Competition with natural L-amino acids. J Nucl Med 32: 1225–1228, 1991.

43.

Weckesser

Langen

: Comparison of ¹²³I-α-Methyltyrosine SPECT and ¹¹C-L-Methionine PET in patients with brain tumors. In: Radioactive Isotopes in Clinical Medicine and research, Advances in Pharmacological Sciences, Basel 1995, 71–75.

44.

Reiche

Nieder

: CCT/MRT patterns of cerebral radiation necrosis after external radiation in brain tumors in comparison to functional neuroimaging. (abstr.) J Neu-rooncol 30: 98, 1996.

45.

Kazner

Wende

, (eds): Computer- und Kernspin-tomographie intrakranieller Tumoren aus klinischer Sicht. Springer, Berlin Heidelberg 1988: 17–41.

46.

Atlas

Lavi

: Intra-axial brain tumors. In: Atlas

, (ed): Magnetic resonance imaging of the brain and spine. Lippincott-Raven, Philadelphia New York 1996: 423–488.

47.

Schwaiger

Ziegler

: PET mit Koinzidenzkamera versus Ringtomograph, Fortschritt oder Rückschritt? Nuklearmedizin 36: 3–5, 1997.